Determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance

International Journal of Psychiatry in Clinical Practice

Volumn 14, Issue 1, 2010, Pages 41-46

  Mennickent, S ^a   Sobarzo, A ^a   Vega, M ^a   De Diego, M ^a   Godoy, G ^a   Rioseco, P ^a,b   Saavedra, L ^a,b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b Hospital Regional de Concepcion Dr Guillermo Grant Benavente   (Chile)

Author keywords

Adherence; Clozapine; Compliance; Drugs; Instrumental planar chromatography; Serum

Indexed keywords

ATENOLOL; CHLORDIAZEPOXIDE; CLONAZEPAM; CLOZAPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FAMOTIDINE; FLUNITRAZEPAM; FLUOXETINE; HALOPERIDOL; HYDROCHLOROTHIAZIDE; LITHIUM; PROPRANOLOL; RANITIDINE; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; STEADY STATE; TREATMENT DURATION;

EID: 77649138928     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651500903434453     Document Type: Article

References (22)

1. Sweetman S. Martindale, Guía Completa de Consulta Farma-coterapéutica. 1st ed. Barcelona: Pharma Editores S.L., 2003.
2. Alastair JJ, Wood MD. Schizophrenia. New Engl J Med 2003;349(18):1738-49.
3. Hardman J, Limbird L. Goodman&Gilman. Las bases farma- cológicas de la terapéutica. 10th ed. México: McGraw-Hill, 2003.
4. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. J Am Med Assoc 2003;290(20):2693-702.
5. Patel N, Crismon L, Miller A, Johnsrud M. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005;25(9):1242-47.
6. Rzewuska M. Drug maintenance treatment compliance and its correlation with the clinical picture and course of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4):811-14.
7. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106(4):286-90.
8. Loffler W, Killian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and non-compliance with neuroleptic treatment. Pharmacopsychiatry 2003;36(3):105-12.
9. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related non-affective psychoses. Drugs 2003;63(21):2265-83.
10. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):24-33.
11. Kampman O, Laippala P, Vaanamen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002;110(1):39-48.
12. Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on intervention: enhance compliance with antipsychotic medication. Psychiatr Ment Health Nurs 2002;9(3):277-84.
13. Marder SR. Overview of partial compliance. J Clin Psychiat-try 2003;64(Suppl 16):3-9.
14. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes. A systematic review. Psychol Med 2003;33(7):1149-60.
15. Baloush-Kleinman V, Poyurovsky M, Koren D, Schneidman M, Weizman A, Shnitt D. Adherence to antipsychotic medication in schizophrenia patients. Harefuah 2002;141(12): 1042-9, 1090.
16. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical consideration and research implications. Encephale 2002;28(3 Pt 1): 266-72.
17. Perkins DO. Predictors for non-compliance in patients with schizophrenia. J Clin Psychiatry 2002;63(12):1121-28.
18. Day J, Bentall R, Robert C, et al. Attitudes toward antipsy-chotic medication. The impact of variables and relationships with health professionals. Gen Psychiatry 2005; 62(7):717-24.
19. Osterbergs L, Blachske T. Adherence to medication. New Engl J Med 2005;353(5):487-497.
20. McEvoy G. AHFS drug information. 48th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2006.
21. Mennickent S, Sobarzo A, Vega M, de Diego M, Godoy G, Rioseco P, et al. Quantitative determination of clozapine in serum by instrumental planar chromatography. J Sep Sci 2007;30(13):2167-72.
22. Van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P 450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Phar-macogenetics 2003;13(3):169-72.